Trial Profile
Antiviral Effect, Safety, and Pharmacokinetics of 5 Days' Oral Administration of deleobuvir, an Investigational HCV RNA Polymerase Inhibitor, in Patients With Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jul 2013
Price :
$35
*
At a glance
- Drugs Deleobuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 24 Jul 2013 New trial record